Teva, Active Biotech phase 2b study of laquinimod meets primary endpoint, triggers milestone

By Lisa Kerner

Charlotte, N.C., Sept. 5 - Teva Pharmaceutical Industries Ltd and Active Biotech AB said a phase 2b study evaluating the safety and efficacy of laquinimod, a once-daily novel oral agent, in relapsing remitting multiple sclerosis patients met its primary endpoint.

In addition, the positive result triggers a milestone payment to Lund, Sweden-based Active Biotech.

Laquinimod reduced the rate of inflammatory disease activity, as measured by the number of Gadolinium enhancing lesions on brain MRI scans, after 36 weeks of treatment.

Approximately 300 patients were enrolled in the phase 2b multi-center, randomized, double-blind, placebo-controlled study in 8 European countries and in Israel.

Further details about the study will be released on Sept. 26.

Teva is a pharmaceutical based in Jerusalem, Israel.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.